Important Safety Information
- ARESTIN is contraindicated in any patient who has a known sensitivity to minocycline or tetracyclines. Hypersensitivity reactions and hypersensitivity syndrome that included, but were not limited to anaphylaxis, anaphylactoid reaction, angioneurotic edema, urticaria, rash, eosinophilia, and one or more of the following: hepatitis, pneumonitis, nephritis, myocarditis, and pericarditis may be present. Swelling of the face, pruritus, fever and lymphadenopathy have been reported with the use of ARESTIN. Some of these reactions were serious. Post-marketing cases of anaphylaxis and serious skin reactions such as Stevens Johnson syndrome and erythema multiforme have been reported with oral minocycline, as well as acute photosensitivity reactions.
- THE USE OF DRUGS OF THE TETRACYCLINE CLASS DURING TOOTH DEVELOPMENT MAY CAUSE PERMANENT DISCOLORATION OF THE TEETH, AND THEREFORE SHOULD NOT BE USED IN CHILDREN OR IN PREGNANT OR NURSING WOMEN.
- Tetracyclines, including oral minocycline, have been associated with development of autoimmune syndromes including a lupus-like syndrome manifested by arthralgia, myalgia, rash, and swelling. Sporadic cases of serum sickness-like reaction have presented shortly after oral minocycline use, manifested by fever, rash, arthralgia, lymphadenopathy and malaise. In symptomatic patients, diagnostic tests should be performed and ARESTIN treatment discontinued.
- The use of ARESTIN in an acutely abscessed periodontal pocket or for use in the regeneration of alveolar bone has not been studied. The safety and effectiveness of ARESTIN has not been established in immunocompromised patients or in those with coexistent oral candidiasis. Use with caution if there is a predisposition to oral candidiasis.
- In clinical trials, the most frequently reported nondental treatment-emergent adverse events were headache, infection, flu syndrome, and pain.
To report SUSPECTED ADVERSE REACTIONS, contact Bausch Health US, LLC at 1‑800‑321‑4576 or FDA at 1‑800‑FDA‑1088 or
www.fda.gov/medwatch.
Please see the Important Safety Information and click here for
full Prescribing Information.
Indication
ARESTIN® (minocycline HCl) Microspheres, 1mg is indicated as an adjunct to scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis. ARESTIN® may be used as part of a periodontal maintenance program, which includes good oral hygiene and SRP.
Important Information Regarding your Account
You are hereby notified that you are receiving a discount on the ARESTIN product purchased, as reflected in the net price shown on your invoices. This discount is being provided and accepted in accordance with the provisions of 42 U.S.C. 1320a-7b(b)(3)(A). Receipt of the discount means you must comply with the requirement of 42 U.S.C. 1320a-7b(b)(3)(A) and the “safe harbor” regulations regarding discounts or other reductions in price set forth at 42 U.S.C.1001-952(h). You must fully and accurately report the existence of such a discount as well as the net cost of the ARESTIN product to Medicare, Medicaid, or any other federal or state health insurance program or any private program in any filings of your costs you may submit to such programs.
- Offer only valid when 2 ARESTIN boxes are purchased together
- All subsequent orders will be at list price
- Offer valid from June 1, 2023 to December 28, 2023 at 12:00pm EST
- Arestin Elite Program members and DSOs are not eligible for this offer
- Offer only applicable for new customers without purchase history
- Offer can only be used once